Yifang Biotech (688382.SH): Nomelcitinib (D-2570) Phase III clinical study for moderate to severe plaque psoriasis reached the main end

Zhitongcaijing · 11/01 08:17

Zhitong Finance App News, Yifang Biotech (688382.SH) announced that the registered phase III clinical study of nomelcitinib (D-2570), a novel oral selective inhibitor targeting Tyk2JH2 developed by the company to treat moderate to severe plaque psoriasis, reached a major end point and a key secondary end point. The results of this study mark a milestone in the clinical development of nomelcitinib (D-2570) in the field of psoriasis.

During this study, nomelcitinib (D-2570) showed good safety and tolerability. The safety characteristics were similar to previous phase II clinical studies and other selective TYK2JH2 inhibitors, and no new safety signals were found.